bispecific

Biointron is excited to announce our participation in the 16th World Bispecific Summit 2025, taking place in Boston, MA, in September 2025. This premier event is dedicated to the development and advancement of bispecific antibodies. This summit serves as a key platform for industry leaders, researchers, and innovators to explore the latest breakthroughs in bispecific antibody engineering, therapeutic applications, and clinical advancements.

Biparatopic antibodies (bpAbs) are bispecific antibodies which bind distinct, non-overlapping epitopes on an antigen. This unique binding mode allows for superior affinity and specificity, promotes antagonism, locks target conformation, and results in higher-order target clustering. The antibody-target complexes can elicit strong agonism, increase immune effector function, or result in rapid target downregulation and lysosomal trafficking.

This month, two high-profile deals for bispecific antibodies targeting the PD-1/PD-L1 and VEGF pathways were announced. The DealsOn November 14, Merck announced its licensing agreement with LaNova Medicines for LM-299, an investigational PD-1/VEGF bispecific antibody. Merck is committing up to

Bispecific antibodies fight cancer via unique mechanisms. Biointron highlights how bsAbs target multiple pathways to expand therapeutic impact.

Bispecific antibodies are rapidly transforming the therapeutic landscape, especially in oncology and autoimmune diseases. Such recombinant molecules can bind to two different antigens at the same time, offering greater specificity in targeting disease pathways. Since their introduction, the area of bispecifics has held tremendous promise in oncological cancers like multiple myeloma and lymphomas.

High-throughput antibody expression drives speed and scale. Biointron applies automated platforms to deliver reproducible antibodies for research and therapy.

Innovative antibody formats like VHHs, scFvs, and ADCs expand therapeutic options. Biointron explores how these formats drive flexibility and efficacy.

Bispecific antibodies target two antigens simultaneously. Biointron explains their advantages and role in advancing next-generation therapeutic development.

The 15th World Bispecifics Summit in Boston showcased breakthroughs. Biointron shares highlights shaping the future of bispecific antibody therapeutics.

Bispecific antibodies transform in vivo research. Biointron highlights how BsAbs expand therapeutic potential by targeting multiple pathways with precision.

The approval of Eli Lilly’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements in the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology.

We are delighted to announce that Biointron will be participating in the 15th Annual World Bispecific Summit, scheduled to take place from September 3 to 5, 2024, in Boston, Massachusetts. This summit is a cornerstone event for the bispecific antibody community, attracting thought leaders and industry experts worldwide to discuss the latest innovations and breakthroughs in bispecific therapeutics.

PEGS Boston 2024 spotlighted protein and antibody engineering advances. Biointron reports event highlights that define the next era of therapeutic innovation.

scFvs combine compact design with strong binding. Biointron explores their history, therapeutic applications, and role in diagnostics and research innovation.

Bispecific ADCs advance oncology. Biointron shows how dual-targeted antibody-drug conjugates improve precision, efficacy, and patient outcomes in cancer treatment.